Annexon, Inc. (ANNX) on Monday announced positive topline results from a real-world evidence study supporting ANX005 as a potential treatment for Guillain-Barr Syndrome, a rapid-onset and acute neuromuscular disease.
The company found that patients treated with ANX005 showed faster and greater improvement in muscle strength and disability compared to patients in the matched International GBS Outcomes Study cohort treated with IVIg or PE.
Also, ANX005-treated patients were observed to spend less time on ventilation and less time in the intensive care unit, and only a few of these patients required mechanical ventilation.
Following the promising results, the company plans to submit a U.S. Biologics License application in the first half of 2025.
Currently, Annexon's stock is climbing 11.15 percent, to $4.94 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.